A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

October 1, 2026

Conditions
IgA Nephropathy (IgAN)C3 GlomerulopathyIC-MPGN
Interventions
DRUG

SGB-9768

SGB-9768 for subcutaneous (SC) injection

Trial Locations (11)

Unknown

Peking University First Hospital, Beijing

Peking University People's Hospital, Beijing

The Third Xiangya Hospital of Central South University, Changsha

Sichuan Provincial People's Hospital, Chengdu

Guizhou Provincial People's Hospital, Guiyang

The affiliated hospital of Guizhou medical university, Guiyang

The first affiliated hospital, Zhejiang university school of medicine, Hangzhou

Huashan hospital, Shanghai

Northern Jiangsu People's Hospital, Yangzhou

General hospital of ningxia medical university, Yinchuan

Henan Provincial People's Hospital, Zhengzhou

All Listed Sponsors
lead

Suzhou Sanegene Bio Inc.

INDUSTRY